Reversible Posterior Leukoencephalopathy Syndrome Induced by Pazopanib

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Chelis, Leonidas ^a   Souftas, Vasilios ^b   Amarantidis, Kiriakos ^a   Xenidis, Nikolaos ^a   Chamalidou, Eleni ^a   Dimopoulos, Prokopios ^a   Michailidis, Prodromos ^a   Christakidis, Evagelos ^a   Prassopoulos, Panagiotis ^b   Kakolyris, Stylianos ^a  

^a UNIVERSITY GENERAL HOSPITAL OF ALEXANDROUPOLIS   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Pazopanib; Renal cell carcinoma; Reversible posterior leukoencephalopathy syndrome

Indexed keywords

ALPHA INTERFERON A; ANTIHYPERTENSIVE AGENT; BEVACIZUMAB; EVEROLIMUS; FENTANYL; FUROSEMIDE; MANNITOL; PAZOPANIB; PERINDOPRIL; PHENYTOIN; SUNITINIB; TRAMADOL;

ADULT; ARTICLE; BRAIN EDEMA; BRAIN RADIOGRAPHY; CASE REPORT; DRUG WITHDRAWAL; FEMALE; HEADACHE; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCIPITAL LOBE; PARIETAL LOBE; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; SALVAGE THERAPY; SEIZURE; SUBCORTICAL EDEMA; TREATMENT RESPONSE; VISUAL IMPAIRMENT;

ADULT; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; POSTERIOR LEUKOENCEPHALOPATHY SYNDROME; PYRIMIDINES; SULFONAMIDES;

EID: 84868200586     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-489     Document Type: Article

References (23)

1. Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, Pessin MS, Lamy C, Mas JL, Caplan LR. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996, 334:494-500. 10.1056/NEJM199602223340803, 8559202.
2. Schwartz RB, Jones KM, Kalina P, Bajakian RL, Mantello MT, Garada B, Holman BL. Hypertensive encephalopathy: findings on CT, MR imaging, and SPECT imaging in 14 cases. AJR Am J Roentgenol 1992, 159(2):379-383.
3. Lee VH, Wijdicks EF, Manno EM, Rabinstein AA. Clinical spectrum of reversible posterior leukoencephalopathy syndrome. Arch Neurol 2008, 65:205-210. 10.1001/archneurol.2007.46, 18268188.
4. Vaughn C, Zhang L, Schiff D. Reversible Posterior Leukoencephalopathy Syndrome in Cancer. Curr Oncol Rep 2008, 10(1):86-91. 10.1007/s11912-008-0013-z, 18366965.
5. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354:980-981.
6. Ozcan C, Wong S, Hari P. Reversible posterior leukoencephalopathy and bevacizumab. N Engl J Med 2006, 354:981-982.
7. Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007, 25:3559. 10.1200/JCO.2007.12.8710, 17687168.
8. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006, 24:48.
9. Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, Coriat R, Goldwasser F. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol 2011, 6(4):253-258. 10.1007/s11523-011-0201-x. Epub 2011 Nov 17, 22090260.
10. Cooksey T, Haji-Michael P. Posterior reversible encephalopathy syndrome associated with deoxycoformycin and alemtuzumab. J R Coll Physicians Edin 2011, 41(3):215-217.
11. Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN, Johnson JH, Knick VB, Laudeman CP, Luttrell DK, Mook RA, Nolte RT, Rudolph SK, Szewczyk JR, Truesdale AT, Veal JM, Wang L, Stafford JA. Discovery of 5-[[4-[(2,3-dimethyl-2Hindazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2- methylbenzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 2008, 51:4632-4640. 10.1021/jm800566m, 18620382.
12. Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov OA, Kavina A, Zarbá JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE. A randomized, double-blind phase lll study of pazopanib in treatment-naïve and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol 2009, 27(15s):A5021.
13. Di Lorenzo G, Porta C, Bellmunt J, Sternberg C, Kirkali Z, Staehler M, Joniau S, Montorsi F, Buonerba C. Toxicities of Targeted Therapy and Their Management in Kidney Cancer. EUROPEAN UROLOGY 2011, 59:526-540. 10.1016/j.eururo.2011.01.002, 21277078.
14. European Medicines Agency http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001141/WC500094272.pdf, European Medicines Agency.
15. Uppsala Monitoring Centre http://www.who-umc.org/Graphics/24734.pdf, Uppsala Monitoring Centre.
16. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30(2):239-245. 10.1038/clpt.1981.154. PMID 7249508, 7249508.
17. Lou E, Turner S, Sumrall A, Reardon DA, Desjardins A, Peters KB, et al. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol 2011,
18. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA. Biomarker analysis and final efficacy and safety results of a phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol 2008, 26:261s. abstr 5046.
19. Strandgaard S, Paulson O. Cerebral autoregulation. Stroke 1994, 15:413-417.
20. Edvinsson L, Oman C, Sjoberg N. Autonomic nerves, mast cells, and amine receptors in human brain vessels. Brain Res 1976, 15:377-393.
21. Marinella MA, Markert RJ. Reversible posterior leucoencephalopathy syndrome associated with anticancer drugs. Intern Med J 2009, 39:826-834. 10.1111/j.1445-5994.2008.01829.x, 19220526.
22. Mendelsohn ME. Genomic and nongenomic effects of estrogen in the vasculature. Am J Cardiol 2002, 90(Suppl):3F-6F.
23. Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999, 340:1801-1811. 10.1056/NEJM199906103402306, 10362825.